{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:52:51Z","timestamp":1781776371803,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05560-8","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:50:53Z","timestamp":1777535453000},"page":"2291-2298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the off-label use of liraglutide in the treatment of obesity: a review"],"prefix":"10.1007","volume":"481","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3892-1764","authenticated-orcid":false,"given":"Carla Bruna Amorim","family":"Braga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2275-0814","authenticated-orcid":false,"given":"Jo\u00e3o Paulo Viana Ara\u00fajo","family":"Segundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-6411","authenticated-orcid":false,"given":"Carlos Alberto Alves Dias","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"2","key":"5560_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4274\/jcrpe.galenos.2023.2023-3-2","volume":"15","author":"N Faccioli","year":"2023","unstructured":"Faccioli N, Poitou C, Cl\u00e9ment K, Dubern B (2023) Current treatments for patients with genetic obesity. J Clin Res Pediatr Endocrinol 15(2):108\u2013119. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2023.2023-3-2","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"16","key":"5560_CR2","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.3390\/nu16162781","volume":"16","author":"G Gallo","year":"2024","unstructured":"Gallo G, Desideri G, Savoia C (2024) Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management. Nutrients 16(16):2781. https:\/\/doi.org\/10.3390\/nu16162781","journal-title":"Nutrients"},{"issue":"13","key":"5560_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449","volume":"24","author":"MS Popoviciu","year":"2023","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G, Metwally K, Cavalu S (2023) Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 24(13):10449. https:\/\/doi.org\/10.3390\/ijms241310449","journal-title":"Int J Mol Sci"},{"key":"5560_CR4","unstructured":"Collins L, Costello RA (2024) Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls. StatPearls Publishing"},{"key":"5560_CR5","unstructured":"Cerillo JL, Parmar M (2024) Liraglutide. In: StatPearls. StatPearls Publishing"},{"key":"5560_CR6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/CLEP.S391819","volume":"14","author":"Z Xie","year":"2022","unstructured":"Xie Z, Yang S, Deng W, Li J, Chen J (2022) Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clin Epidemiol 14:1463\u20131476. https:\/\/doi.org\/10.2147\/CLEP.S391819","journal-title":"Clin Epidemiol"},{"issue":"3","key":"5560_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s41669-025-00561-7","volume":"9","author":"P Papantoniou","year":"2025","unstructured":"Papantoniou P, Maniadakis N (2025) Semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece: a short-term cost-effectiveness analysis. PharmacoEconomics - Open 9(3):487\u2013497. https:\/\/doi.org\/10.1007\/s41669-025-00561-7","journal-title":"PharmacoEconomics - Open"},{"issue":"2","key":"5560_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT, STEP 8 Investigadores (2022) Efeito da Semaglutida Subcut\u00e2nea Semanal vs Liraglutida Di\u00e1ria no Peso Corporal em Adultos com Sobrepeso ou Obesidade sem Diabetes: O Ensaio Cl\u00ednico Randomizado STEP 8. JAMA 327(2):138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"issue":"8","key":"5560_CR9","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/oby.23481","volume":"30","author":"D Maselli","year":"2022","unstructured":"Maselli D, Atieh J, Clark MM, Eckert D, Taylor A, Carlson P, Burton DD, Busciglio I, Harmsen WS, Vella A, Acosta A, Camilleri M (2022) Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obes (Silver Spring Md) 30(8):1608\u20131620. https:\/\/doi.org\/10.1002\/oby.23481","journal-title":"Obes (Silver Spring Md)"},{"issue":"2","key":"5560_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/dom.14880","volume":"25","author":"W Sannaa","year":"2023","unstructured":"Sannaa W, Dilmaghani S, BouSaba J, Maselli D, Atieh J, Eckert D, Taylor AL, Harmsen WS, Acosta A, Camilleri M (2023) Factors associated with successful weight loss after liraglutide treatment for obesity. Diabetes Obes Metab 25(2):377\u2013386. https:\/\/doi.org\/10.1111\/dom.14880","journal-title":"Diabetes Obes Metab"},{"key":"5560_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100853","volume":"39","author":"D Papamargaritis","year":"2024","unstructured":"Papamargaritis D, Al-Najim W, Lim JZM, Crane J, Bodicoat DH, Barber S, Lean M, McGowan B, O\u2019Shea D, Webb DR, Wilding JPH, le Roux CW, Davies MJ (2024) Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial. Lancet Reg Health Eur 39:100853. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100853","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"5560_CR12","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/dom.13827","volume":"21","author":"OM Farr","year":"2019","unstructured":"Farr OM, Upadhyay J, Rutagengwa C, DiPrisco B, Ranta Z, Adra A, Bapatla N, Douglas VP, Douglas KAA, Nolen-Doerr E, Mathew H, Mantzoros CS (2019) Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab 21(11):2459\u20132464. https:\/\/doi.org\/10.1111\/dom.13827","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"5560_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41366-023-01370-w","volume":"47","author":"G Coppin","year":"2023","unstructured":"Coppin G, Mu\u00f1oz Tord D, Pool ER, Locatelli L, Achaibou A, Erdemli A, Le\u00f3n P\u00e9rez L, Wuensch L, Cereghetti D, Golay A, Sander D, Pataky Z (2023) A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity. Int J Obes Lond 47(12):1224\u20131231. https:\/\/doi.org\/10.1038\/s41366-023-01370-w","journal-title":"Int J Obes Lond"},{"issue":"1","key":"5560_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/oby.23596","volume":"31","author":"S Santini","year":"2023","unstructured":"Santini S, Vionnet N, Pasquier J, Gonzalez-Rodriguez E, Fraga M, Pitteloud N, Favre L (2023) Marked weight loss on liraglutide 3.0\u00a0mg: real-life experience of a Swiss cohort with obesity. Obes (Silver Spring Md) 31(1):74\u201382. https:\/\/doi.org\/10.1002\/oby.23596","journal-title":"Obes (Silver Spring Md)"},{"issue":"5","key":"5560_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000518325","volume":"14","author":"CL Haase","year":"2021","unstructured":"Haase CL, Achenbach S, Lucrezi MG, Jeswani G, Maurer N, S., Egermann U (2021) Use of Liraglutide 3.0\u00a0mg for Weight Management in a Real-World Setting in Switzerland. Obes Facts 14(5):568\u2013576. https:\/\/doi.org\/10.1159\/000518325","journal-title":"Obes Facts"},{"issue":"1","key":"5560_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cob.12226","volume":"8","author":"RL Kolotkin","year":"2018","unstructured":"Kolotkin RL, Smolarz GB, Meincke HH, Fujioka K (2018) Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes 8(1):1\u201310. https:\/\/doi.org\/10.1111\/cob.12226","journal-title":"Clin Obes"},{"issue":"2","key":"5560_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023780","volume":"100","author":"JS Park","year":"2021","unstructured":"Park JS, Kwon J, Choi HJ, Lee C (2021) Clinical effectiveness of liraglutide on weight loss in South Koreans: first real-world retrospective data on Saxenda in Asia. Medicine (Baltimore) 100(2):e23780. https:\/\/doi.org\/10.1097\/MD.0000000000023780","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"5560_CR18","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.26355\/eurrev_202405_36181","volume":"28","author":"M Alshahawey","year":"2024","unstructured":"Alshahawey M, Ghazy M, El Morshedy M, El Said NO (2024) Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis. Eur Rev Med Pharmacol Sci 28(9):3365\u20133374. https:\/\/doi.org\/10.26355\/eurrev_202405_36181","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5560_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351. https:\/\/doi.org\/10.1016\/j.molmet.2021.101351","journal-title":"Mol Metab"},{"issue":"1","key":"5560_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jcp.30581","volume":"237","author":"L Del Bosque-Plata","year":"2022","unstructured":"Del Bosque-Plata L, Hern\u00e1ndez-Cort\u00e9s EP, Gragnoli C (2022) The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetes. J Cell Physiol 237(1):301\u2013312. https:\/\/doi.org\/10.1002\/jcp.30581","journal-title":"J Cell Physiol"},{"issue":"7","key":"5560_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrn875","volume":"3","author":"MG Baxter","year":"2002","unstructured":"Baxter MG, Murray EA (2002) The amygdala and reward. Nat Rev Neurosci 3(7):563\u2013573. https:\/\/doi.org\/10.1038\/nrn875","journal-title":"Nat Rev Neurosci"},{"issue":"3\u20134","key":"5560_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS (2014) Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 11(3\u20134):202\u2013230. https:\/\/doi.org\/10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"issue":"1","key":"5560_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","volume":"12","author":"JJ Gorgojo-Mart\u00ednez","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, Castro A, Cebri\u00e1n-Cuenca A, de Torres-S\u00e1nchez A, Garc\u00eda-de-Lucas MD, N\u00fa\u00f1ez J, Obaya JC, Soler MJ, G\u00f3rriz JL, Rubio-Herrera M\u00c1 (2022) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med 12(1):145. https:\/\/doi.org\/10.3390\/jcm12010145","journal-title":"J Clin Med"},{"issue":"46","key":"5560_CR24","doi-asserted-by":"publisher","first-page":"e1375252025","DOI":"10.1523\/JNEUROSCI.1375-25.2025","volume":"45","author":"J Guo","year":"2025","unstructured":"Guo J, Hayes MR, Leggio L, Oru E, Rinaman L (2025) GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders. J Neurosci 45(46):e1375252025. https:\/\/doi.org\/10.1523\/JNEUROSCI.1375-25.2025","journal-title":"J Neurosci"},{"issue":"3","key":"5560_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.7570\/jomes22029","volume":"31","author":"HJ Ko","year":"2022","unstructured":"Ko HJ, Kim JW, Lim S (2022) Adherence to and dropout from liraglutide 3.0\u00a0mg obesity treatment in a real-world setting. J Obes Metab Syndr 31(3):254\u2013262. https:\/\/doi.org\/10.7570\/jomes22029","journal-title":"J Obes Metab Syndr"},{"issue":"8","key":"5560_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","volume":"30","author":"PP Gleason","year":"2024","unstructured":"Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS (2024) Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm 30(8):860\u2013867. https:\/\/doi.org\/10.18553\/jmcp.2024.23332","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"5560_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.18553\/jmcp.2025.31.5.441","volume":"31","author":"L Liu","year":"2025","unstructured":"Liu L, Cui J, Neidecker MV, Nahata MC (2025) Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: a short-term cost-effectiveness analysis in the United States. J Manag Care Spec Pharm 31(5):441\u2013450. https:\/\/doi.org\/10.18553\/jmcp.2025.31.5.441","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"5560_CR28","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s13300-023-01462-w","volume":"14","author":"A Esteghamati","year":"2023","unstructured":"Esteghamati A, Zamanzadeh M, Malek M, Khaledi M, Monavari A, Najafi L, Banazadeh Z, Malboosbaf R, Aghili R, Mahdikhah S, Ganjizadeh-Zavereh H, Kafi H, Hosseinpanah F, Khamseh ME (2023) Efficacy and safety of a biosimilar liraglutide (Melitide\u00ae) versus the reference liraglutide (Victoza\u00ae) in people with type 2 diabetes mellitus: a randomized, double-blind, noninferiority clinical trial. Diabetes Ther 14(11):1889\u20131902. https:\/\/doi.org\/10.1007\/s13300-023-01462-w","journal-title":"Diabetes Ther"},{"key":"5560_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40842-025-00219-7","volume":"11","author":"S Ghosh","year":"2025","unstructured":"Ghosh S, Sethi B, Kalra S, Baruah MP, Mane A, Choudhari S, Petare A, Jadhav M, Patil S, Barkate H (2025) Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial. Cardiovasc Diabetol Endocrinol Rep 11:6. https:\/\/doi.org\/10.1186\/s40842-025-00219-7","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"5560_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.111034","volume":"207","author":"K Krishnan","year":"2024","unstructured":"Krishnan K, Raman S, Moses ACR, Rajesh RP, Gupta A, Mudaliar V, Vimal J (2024) Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 207:111034. https:\/\/doi.org\/10.1016\/j.diabres.2023.111034","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05560-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05560-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05560-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:06:00Z","timestamp":1781773560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05560-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["5560"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05560-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6631957\/v1","asserted-by":"object"}]},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}